Vimarsana
Biggest News Aggregation in the World

Page 5 - Cellular Therapy Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cellular Therapy Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cellular Therapy Program Today - Breaking & Trending Today

Win tickets to Taylor Swift's New Orleans 'Eras' tour stop | Music - Vimarsana News

Win tickets to Taylor Swift's New Orleans 'Eras' tour stop | Music

Good news, Swifties. If you were one of the many unlucky Louisiana fans who were waitlisted in the desperate struggle this summer for tickets to one of Taylor Swift's upcoming

Source: nola.com
Faculty Position, Department of Infectious Diseases - Transplant job with St. Jude Children's Research Hospital (St. Jude) - Vimarsana News

Faculty Position, Department of Infectious Diseases - Transplant job with St. Jude Children's Research Hospital (St. Jude)

Faculty Position, Department of Infectious Diseases - Transplant job in Memphis, Tennessee with St. Jude Children's Research Hospital (St. Jude). Apply Today.

Source: nature.com
Orange County chef thanks his daughter, UCI Health medical team for his chance at beating cancer - Vimarsana News

Orange County chef thanks his daughter, UCI Health medical team for his chance at beating cancer

An Orange County chef battling a rare blood cancer found hope thanks to a donation from his daughter in France and the help of his medical team.

Source: abc7.com
Stem cell gene therapy may offer a promising, curative treatment for sickle cell disease - Vimarsana News

Stem cell gene therapy may offer a promising, curative treatment for sickle cell disease

New research published in the New England Journal of Medicine indicates that stem cell gene therapy may offer a promising, curative treatment for the painful, inherited blood disorder sickle cell disease (SCD).

NKX101 Demonstrates Early Activity in Relapsed/Refractory AML - Vimarsana News

NKX101 Demonstrates Early Activity in Relapsed/Refractory AML

Treatment with NKX101 led to a best compositive complete response rate of 67% in patients with relapsed/refractory acute myeloid leukemia, according to updated data from a dose-expansion cohort of an ongoing phase 1 trial.